AndreaBozzo/ceres-open-data-index huggingface dataset:
Patent AT-E400124-T1: [Translated] CONVERTING A COMPLEX VALUE START SIGNAL INTO A COMPLEX VALUE END SIGNAL WITH A HIGHER OR LOWER FREQUENCY

A signal converter for converting a start signal into an end signal includes means for copying the start signal to obtain a plurality of copied start signals, wherein a copied start signal may be fed into a processing branch as a branch signal. Further, the signal converter includes a first branch processing means in a first processing branch for processing a first branch signal according to a first processing regulation to obtain a first processed branch signal. Further, the signal converter includes a second branch processing means in a second processing branch for processing a second branch signal according to a second processing regulation to obtain a second processed branch signal, wherein the second processing regulation is different from the first processing regulation and wherein the first processing regulation and the second processing regulation are implemented to cause a low-pass polyphase filtering of the copied start signals. Finally, the signal converter includes selection means for sequentially selecting the first processed branch signal and then the second processed branch signal in order to obtain the end signal.
A cohort study of possible risk factors for over-reporting of antihypertensive adherence

Background
          The identification of poor medicinal adherence is difficult because direct observation of medication use is usually impractical. Up to 50% of individuals on chronic therapies may not be taking their medication as prescribed. This study is one of the first to explore possible risk factors for over-reporting of antihypertensive adherence using electronic medication monitoring.
        
        
          Methods
          The adherence of 286 individuals on single-drug antihypertensive therapy in a large managed care organization was electronically monitored for approximately three months. Questionnaires on socioeconomic background, adherence to therapy, health beliefs, and social support before and after adherence monitoring were completed. Over-reporting of antihypertensive adherence was assessed by comparing the self-reported frequency of noncompliance with that determined from electronic dosing records. Risk factors for over-reporting were identified by contingency table analysis and step-wise logistic regression.
        
        
          Results
          Although only 21% of participants acknowledged missing doses on one or more days per week, electronic monitoring documented nonadherence at this or a higher level in 42% of participants. The following variables were associated with over-reporting: >1 versus 1 daily dose (OR = 2.58; 95% CI = 1.50–4.41; p = .0006), lower perceived health risk from nonadherence (OR = 1.35; 95% CI = 1.10–1.64; p = .0035), and annual household income of <$15,000 versus >$30,000 (OR = 2.64; 95% CI = 1.13–6.18; p = .025).
        
        
          Conclusions
          Over-reporting of adherence may be affected by factors related to dosing frequency, health beliefs and socioeconomic status. This topic deserves further investigation in other patient populations to elucidate possible underlying behavioral explanations.
Patent AT-E400762-T1: [Translated] PIPE, ESPECIALLY FOR AIR INLET CIRCUIT OF A VEHICLE ENGINE

The invention relates to a pipe which is intended, in particular, for an air intake circuit in a motor vehicle engine. The inventive pipe is characterised in that it consists of a structure comprising at least: an inner layer (10) which is made from a polar material that is at least partially formed from an elastomer selected from ethylene and acrylic acid copolymers, ethylene and vinyl acetate copolymers or acrylate polymers; a flexible outer layer (16) which is formed from an apolar material such as an EPDM; and an intermediate layer (12) which facilitates the adhesion between the inner and outer layer (10 and 16).
COVID-19 State Profile Report - North Dakota

<b>After over two years of public reporting, the State Profile Report will no longer be produced and distributed after February 2023. The final release was on February 23, 2023. We want to thank everyone who contributed to the design, production, and review of this report and we hope that it provided insight into the data trends throughout the COVID-19 pandemic.
Data about COVID-19 will continue to be updated at <a href='https://covid.cdc.gov/covid-data-tracker/#datatracker-home' >CDC’s COVID Data Tracker</a>.
 </b>

<p>
The State Profile Report (SPR) is generated by the Data Strategy and Execution Workgroup in the Joint Coordination Cell, in collaboration with the White House. It is managed by an interagency team with representatives from multiple agencies and offices (including the United States Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention, the HHS Assistant Secretary for Preparedness and Response, and the Indian Health Service). The SPR provides easily interpretable information on key indicators for each state, down to the county level.
 </p>

It is a weekly snapshot in time that:
<ul>
<li>Focuses on recent outcomes in the last seven days and changes relative to the month prior</li>
<li>Provides additional contextual information at the county level for each state, and includes national level information</li>
<li>Supports rapid visual interpretation of results with color thresholds</li>
</ul>
Impaired wound healing in mice deficient in a matricellular protein SPARC (osteonectin, BM-40)

Background
          SPARC is a matricellular protein involved in cell-matrix interactions. From expression patterns at the wound site and in vitro studies, SPARC has been implicated in the control of wound healing. Here we examined the function of SPARC in cutaneous wound healing using SPARC-null mice and dermal fibroblasts derived from them.
        
        
          Results
          In large (25 mm) wounds, SPARC-null mice showed a significant delay in healing as compared to wild-type mice (31 days versus 24 days). Granulation tissue formation and extracellular matrix protein production were delayed in small 6 mm SPARC-null wounds initially but were resolved by day 6. In in vitro wound-healing assays, while wild-type primary dermal fibroblasts showed essentially complete wound closure at 11 hours, wound closure of SPARC-null cells was incomplete even at 31 hours. Addition of purified SPARC restored the normal time course of wound closure. Treatment of SPARC-null cells with mitomycin C to analyze cell migration without cell proliferation showed that wound repair remained incomplete after 31 hours. Cell proliferation as measured by 3H-thymidine incorporation and collagen gel contraction by SPARC-null cells were not compromised.
        
        
          Conclusions
          A significant delay in healing large excisional wounds and setback in granulation tissue formation and extracellular matrix protein production in small wounds establish that SPARC is required for granulation tissue formation during normal repair of skin wounds in mice. A defect in wound closure in vitro indicates that SPARC regulates cell migration. We conclude that SPARC plays a role in wound repair by promoting fibroblast migration and thus granulation tissue formation.
Patent AT-E401799-T1: [Translated] METHOD FOR PRODUCING spreadable liver sausage

The method involves having raw meat materials sent through a cutter and which are then emulsified into a homogeneous mass and filled into a following intestine, and then heated. The raw materials are made into a broth and by addition of warm water, activate the emulsifying agent, and mixed to the homogeneous mass and or cut parts. After stuffing the homogeneous mass into the intestine the final product is cooled down such that it is becomes spreadable. The raw meat material may be beef, pork, bacon, and or pig liver.
Patent AT-E400003-T1: [Translated] LIQUID CRYSTAL DISPLAYS WITH IMPROVED GRAYSCALE

A liquid crystal display with improved gray-scale display. The liquid crystal display includes a plurality of pixel areas (P), each including first (200) and second (600) substrates disposed opposite each other and a liquid crystal layer (640) interposed therebetween. A first pixel electrode (265) and a first pixel driving device (245) electrically connected thereto are formed on part of the first substrate. A second pixel electrode (260) and a second pixel driving device (244) electrically connected thereto are formed on part of the first substrate. A common electrode (620) is formed on the interior of the second substrate. The first and second pixel driving devices have mutually different ON currents, resulting in the first and second pixel electrodes having mutually different voltages.
Compound 526823: Palmitic acid, 12-tert-butyldimethylsilyloxy-, methyl ester

Chemical compound data from PubChem database. IUPAC Name: methyl 12-[tert-butyl(dimethyl)silyl]oxyhexadecanoate. Molecular Formula: C23H48O3Si. Molecular Weight: 400.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Lung Toxicity Profile of Inhaled Copper-Nickel Welding Fume in A/J Mice

The process of stainless steel welding creates fumes rich in carcinogenic metals such as chromium (Cr). Welding consumables devoid of Cr are being produced in attempt to limit worker exposures to potentially toxic and carcinogenic metals. The study objective was to characterize a copper-nickel (Cu-Ni) fume generated using gas metal arc welding (GMAW) and determine the pulmonary deposition and toxicity of the fume in mice exposed by inhalation. Male A/J mice (6 – 8 weeks of age) were exposed to air or Cu-Ni welding fumes for 2 (low deposition) or 4 (high deposition) hours/day for 10 days. Mice were sacrificed and bronchoalveolar lavage (BAL), macrophage function, and histopathological analysis were performed at various timepoints post-exposure to evaluate resolution. Characterization of the fume indicated that most of the particles were between 0.1 and 1 µm in diameter, with a mass median aerodynamic diameter of 0.43 µm. Metal content of the fume was primarily Cu (~76%) and Ni (~12%). After exposure, BAL macrophages had a reduced ability to phagocytose E. coli at 1 and 7 days and lung cytotoxicity was evident and significant (>12-19% fold change). Loss of body weight was also significant at these two early timepoints. Lung inflammation, the predominant lesion identified by histopathology, was observed as a subacute response early that progressively resolved by 28 days with only macrophage aggregates remaining late (84 days). Future studies are planned to investigate the tumorigenic potential of Cu-Ni fume in A/J mice.
CB Fact Sheet

The Children’s Bureau (CB), an agency within the Administration for Children and Families within the U.S. Department of Health and Human Services, seeks to improve the safety, permanency, and well-being of children through leadership, support for necessary services, and productive partnerships with states, tribes, and communities. It provides leadership in addressing the prevention of child abuse and neglect.

CB has the primary responsibility for administering federal programs that support state child welfare services. With an annual budget of almost $12 billion, CB provides support and guidance to programs that focus on:

Metadata-only record linking to the original dataset. Open original dataset below.
Chronic obstructive pulmonary disease, asthma and protective effects of food intake: from hypothesis to evidence?

Evidence for a role of diet in asthma and chronic obstructive pulmonary disease (COPD) has been accumulating rapidly over the past decade. Associations have been reported between the intake of fruit, fish, antioxidant vitamins, fatty acids, sodium or magnesium, and indicators of asthma and COPD. Several issues need to be addressed before causality of these associations can be established. The role of diet in the development of disease and the induction time and reversibility of the effect needs further investigation. The role of smoking habits in the relation of diet and respiratory disease also needs to be elucidated. Nevertheless, based on the available evidence, dietary guidelines could be proposed for the primary and secondary prevention of asthma and COPD that are in line with existing dietary guidelines for the prevention of coronary heart disease and cancer.
Melatonin reduces TNF-a induced expression of MAdCAM-1 via inhibition of NF-kB.

Background
          Endothelial MAdCAM-1 (mucosal addressin cell adhesion molecule-1) expression is associated with the oxidant-dependent induction and progress of inflammatory bowel disease (IBD). Melatonin, a relatively safe, potent antioxidant, has shown efficacy in several chronic injury models may limit MAdCAM-1 expression and therefore have a therapeutic use in IBD.
        
        
          Methods
          We examined how different doses of melatonin reduced endothelial MAdCAM-1 induced by TNF-a in an in vitro model of lymphatic endothelium. Endothelial monolayers were pretreated with melatonin prior to, and during an exposure, to TNF-a (1 ng/ml, 24 h), and MAdCAM-1 expression measured by immunoblotting.
        
        
          Results
          MAdCAM-1 was induced by TNF-a. Melatonin at concentrations over 100 μm (10-4 M) significantly attenuated MAdCAM-1 expression and was maximal at 1 mM.
        
        
          Conclusions
          Our data indicate that melatonin may exert therapeutic activity in IBD through its ability to inhibit NF-kB dependent induction of MAdCAM-1.
National Estimates of Drug-Related Emergency Department Visits, 2004-2011 - All Misuse and Abuse

Excel file with national estimates, rates, relative standard errors, trends and confidence intervals for all drug-related emergency department (ED) visits involving drug misuse or abuse, covering 2004-2011. Drug misuse/abuse visits include the use of illicit drugs, nonmedical use of pharmaceuticals, underage drinking and visits where alcohol was combined with another drug.
Treatment Episode Data Set (TEDS): 2017 Admissions to and Discharges from Publicly-Funded Substance Use Treatment

This report presents national- and state-level data from the Treatment Episode Data Set (TEDS) for admissions and discharges occurring in 2017, and trend data from 2007 to 2017. It summarizes demographic information and the characteristics and outcomes of treatment for alcohol and/or drug use among clients aged 12 years and older in facilities that report to individual state administrative data systems. Data include records for treatment admissions and discharges that were received and processed through November 21, 2018. TEDS records do not represent individuals; rather, each record represents a treatment episode. Thus, an individual admitted to treatment twice within a calendar year is counted as two admissions. Similarly, discharges during the year, regardless of when the admission occurred, are counted. TEDS does not include all substance use treatments. It includes treatment admissions and discharges at facilities that are licensed or certified by a state substance abuse agency to provide care for people with a substance use disorder (or facilities that are administratively tracked for other reasons). In general, facilities reporting TEDS data are those that receive state alcohol and/or drug agency funds (including federal block grant funds) for the provision of alcohol and/or drug treatment services. Additional information on the history and methodology of TEDS and this report, as well as important issues related to state data collection systems, are available in Appendix A.
Patent AT-E399632-T1: [Translated] PIPE EXPANSION

A method for widening a plastic or plastic-metal composite tube (10) involves (a) inserting an expandable smoothing bush (28) between a sizing tool (12) with several disengageable expanding segments (20) and the tube (10) and (b) widening the tube (10) by disengaging the segments (20) inside the bush (28) while preserving the homogeneity of the inside of the tube (10). Independent claims are also included for (1) a tube-sizing tool as above, with (a) several expandable segments (20) in a rotationally-symmetrical arrangement, which can be moved radially between an engaged position for insertion into the tube and a disengaged position for widening the tube and (b) an expandable smoothing bush (28) which can be inserted between (20) (engaged position) and the tube and then removed after widening the tube (2) a fitting for connecting tubes as above, comprising (a) a fitting body with a supporting bush onto which the widened end of a tube can be pushed and (b) an expandable smoothing bush for widening the end of a tube with a sizing tool as above.
Compound 528175: 1,3-Cyclopentadiene, 2-decyl

Chemical compound data from PubChem database. IUPAC Name: 2-decylcyclopenta-1,3-diene. Molecular Formula: C15H26. Molecular Weight: 206.37. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528126: 2-Methyl-6-(2-methylbutyl)-3-octylpyrazine

Chemical compound data from PubChem database. IUPAC Name: 3-methyl-5-(2-methylbutyl)-2-octylpyrazine. Molecular Formula: C18H32N2. Molecular Weight: 276.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400095-T1: [Translated] METHOD FOR ASSIGNING AND METHOD FOR ASSOCIATING CODES FOR DATA TRANSMISSIONS BETWEEN A RADIO STATION AND AT LEAST ONE SUBSCRIBER STATION VIA AN AIR INTERFACE OF A RADIO COMMUNICATIONS SYSTEM AND NETWORK-SIDE DEVICE AND R

Chemical patent from PubChem database. Patent Number: AT-E400095-T1. Title: Method of Treatment Using Chemical Compounds. Filing Date: 1999-04-22. Inventors: Yamamoto, Hiroshi, Schmidt, Hans. Abstract: Methods for treating diseases using specific chemical compounds are provided, including dosing regimens and combination therapies for enhanced therape... IPC Classifications: C07H, A61K, A61P. This patent covers 33 claims related to 8 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
Interagency Collaboration to Address Human Trafficking

This Child Welfare Information Gateway Podcast is available on Apple Podcasts
  
  

, GooglePlay
  
  

, Spotify
  
  

, Stitcher
  
  

, SoundCloud
  
  

, and the Child Welfare Information Gateway
  
  

 website. Subscribe to receive new episodes as they are released.

Metadata-only record linking to the original dataset. Open original dataset below.
Provider Network Data: 2022 Quarter 3

This Provider Network Data contains information on individual and institutional providers participating in health plan networks from July through September 2022. Plan network data is collected from Medicaid, Commercial, and Exchange plans on a quarterly basis by the Department of Health, including managed care plans, as well as PPO/EPO plans.

For more information, please visit: <a href=https://pndslookup.health.ny.gov>https://pndslookup.health.ny.gov</a>
Compound 530156: Octadecane, 8-methyl-7-pentyl

Chemical compound data from PubChem database. IUPAC Name: 8-methyl-7-pentyloctadecane. Molecular Formula: C24H50. Molecular Weight: 338.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Departmental Appeals Board Decisions

<p>Decisions issued by the Chair and Board Members of the Departmental Appeals Board concerning determinations in discretionary, project grant programs, including disallowances, terminations and denials of refunding, cost allocation plan disapprovals, and rate determinations; determinations in mandatory grant programs, including disallowances of state claims under titles I, IV-A (Temporary Assistance for Needy Families), IV-D (Child Support Enforcement), IV-E (Foster Care and Adoption Assistance), X, XIV, XVI, XIX (Medicaid), and XXI (State Children's Health Insurance Program) of the Social Security Act; and appellate review of decisions of DAB Civil Remedies Division ALJs, decisions of Food and Drug Administration ALJs regarding civil money penalties, and decisions of Department of the Interior ALJs in Indian Health Service contract/compact cases. .</p>
Compound 527426: Dehydrosabinaketone

Chemical compound data from PubChem database. IUPAC Name: 5-propan-2-ylbicyclo[3.1.0]hex-3-en-2-one. Molecular Formula: C9H12O. Molecular Weight: 136.19. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401680-T1: [Translated] CONNECTOR FOR SIGNAL TRANSMITTING CABLES

A connector for signal transmission cable, comprises a housing (10) with a central axis (12), a carrier unit (26) accommodated in the housing cavity (14) for an arrangement of signal interface elements (28). In the housing cavity (14) is used a special intermediate ring (16) for retaining the carrier unit (26), where the carrier unit and intermediate ring have inter-operating first axial support devices (40,42,26,48), which in the installed state of the carrier unit, support against the intermediate ring in both directions. The housing and the intermediate ring have second axial support devices (30,32,34,36,38), which in the installed condition of the intermediate ring (16) support against the housing (10) in both directions. An independent claim is included for a tool for unlocking the connector.
Changes in cytokine production in healthy subjects practicing Guolin Qigong : a pilot study

Background
          Guolin Qigong is a combination of meditation, controlled breathing and physical movement designed to control the vital energy (qi) of the body and consequently to improve spiritual, physical and mental health. Practice of Qigong has been reported to alter immunological function, but there have been few studies of its effects on cytokines, the key regulators of immunity.
        
        
          Methods
          Numbers of peripheral blood cytokine-secreting cells were determined by ELISPOT in 19 healthy volunteers aged 27 – 55, before they were taught the practice of Qigong and after 3, 7 and 14 weeks of daily practice. The effect of Qigong on blood cortisol was also examined.
        
        
          Results
          Numbers of IL4 and IL12-secreting cells remained stable. IL6 increased at 7 weeks and TNFα increased in unstimulated cultures at 3 and 7 weeks but decreased at these times in LPS and SAC-stimulated cultures. Of particular interest, IFNγ-secreting cells increased and IL10-secreting cells decreased in PHA-stimulated cultures, resulting in significant increases in the IFNγ:IL10 ratio. Cortisol, a known inhibitor of type 1 cytokine production, was reduced by practicing Qigong.
        
        
          Conclusion
          These preliminary studies in healthy subjects, although not necessarily representative of a randomized healthy population and not including a separate control group, have indicated that blood levels of the stress-related hormone cortisol may be lowered by short-term practice of Qigong and that there are concomitant changes in numbers of cytokine-secreting cells. Further studies of the effect of Qigong in patients with clinical diseases known to be associated with type 2 cytokine predominance are merited.